Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

By Yahoo! Finance | Sep 9, 2024 at 02:34 PM EST

BofA Securities upgraded Fulcrum Therapeutics ahead of phase 3 losmapimod readout for FSHD, a rare genetic muscle disease. The company's new study using the "reachable workspace" endpoint has sparked debate among analysts and investors.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.